Anatara Lifesciences (ASX:ANR) Provides GaRP-IBS Trial Update
Trial Progress Update
Anatara Lifesciences (ASX: ANR) has announced a recruitment pause in their pivotal GaRP-IBS (Irritable Bowel Syndrome) clinical trial. The decision comes as the number of enrolled participants has exceeded the minimum target for Stage 2. The number of enrolled individuals stands at 63, with over 30 having already completed the treatment phase. Ongoing screening for more participants continues this week, with a total participant count moving towards the mid-range of the set goal of 60 to 100 participants for Stage 2.
Future Outlook
The company anticipates that analysis results from the trial will be available in March 2025. Dr. David Brookes, Executive Chair of Anatara, expressed gratitude for the efforts from trial sites and participants, stating, “Recruitment has achieved an adequate number of participants, and we look forward to the upcoming analysis which is expected to reinforce the promising findings from Stage 1 of the trial.”
Share Purchase Plan Details
Anatara is set to close its Share Purchase Plan (SPP) for eligible shareholders on 18th December 2024. Shareholders can purchase shares at 0.05 cents, with investments ranging from a minimum of $2,000 to a maximum of $30,000. Funds raised will support further stages of the clinical study and allocate investments towards an anti-obesity project aimed at developing a new oral medication.
Market Potential for IBS Treatment
The GaRP product holds the potential to address significant gastrointestinal disorders, with the market opportunity for non-prescription products in this space estimated at US$8 billion.
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.